UBS Group
BIB icon

UBS Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

UBS Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$13K – 8818
2014
Q4 		$13K Buy
+200
New +$11.7K ﹤0.01% 8136

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group's BIB Position: Q1 2026 in Review

UBS Group held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 1 share worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #10145.

UBS Group first reported a position in BIB in Q4 2014 and has held it in 35 quarters since. The position peaked at $797K in Q3 2020. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • UBS Group held 1 share of ProShares Ultra NASDAQ Biotechnology worth $82 as of Q1 2026.
  • UBS Group left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10145 holding.
  • UBS Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and has held it in 35 quarters since.
  • UBS Group's ProShares Ultra NASDAQ Biotechnology position peaked at $797K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.